NCT06646055Active, not recruitingPhase 1/2
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
A Phase Ib/II Clinical Study of AK112 and Cadonilimab Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 9 Mar 2026
Brief summary (registry, in English)
This trial is a Phase Ib/II study. All patients are stage IV pancreatic cancer (PDAC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and Cadonilimab combined with chemotherapy as first-line treatment for patients with metastatic pancreatic cancer.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- First submitted
- 16 Oct 2024
- Start date
- 21 Jan 2025
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Akeso
- Diseases
- Pancreatic cancer
- NCT number
- NCT06646055
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 110
- From 21 Jan 2025 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Undergoing systemic antiangiogenic therapy.
Other illness
- Other known malignancies within five years.
- Active infection requiring systemic therapy.
Other
- Histological or cytological diagnosis of other pathological types.
- BRCA1/2 or PALB2 mutations.
- Participating in another clinical research.
- Active central nervous system (CNS) metastases.
- Acute or subacute pancreatitis.
Who the study is looking for
- Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).
- ≥18 years old and ≤ 75 years (regardless of sex).
- ECOG performance status 0-1
- Life expectancy longer than 3 months.
- Histologically or cytologically confirmed diagnosis of metastatic pancreatic ductal carcinoma (PDAC).
- No prior systemic anti-tumor therapy for metastatic PDAC.
- Adequate organ function.
- Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.